In this retrospective review of spontaneous postmarketing case reports, data from the FDA Adverse Event Reporting System (FAERS) and PubMed databases were examined between September 25, 2009, and November 20, 2017. The analysis identified twelve instances of new-onset acute and subacute noninfectious pneumonia following the general release of ustekinumab. Cases were excluded if symptoms appeared more than 2 years after starting ustekinumab or if an alternative cause for the noninfectious pneumonia (aside from drug-induced) was documented.

Citation: Brinker A, Cheng C, Chan V. Association of Noninfectious Pneumonia With Ustekinumab Use. JAMA Dermatol. 2019 Feb 1;155(2):221-224. doi: 10.1001/jamadermatol.2018.4118. PMID: 30540343; PMCID: PMC6439534.